Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 82288102 | Other Grant/Funding Number | the National Natural Science Foundation of China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to understand the effect of Metformin on patients with PCOS.
This study aims to evaluate the effects of Metformin on reproductive endocrine and reproductive outcomes in women with PCOS, and to explore its underlying mechanisms to provide the intervention strategies for PCOS.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Metformin intervention for 12 weeks | Experimental | Metformin intervention for 12 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Metformin intervention for 12 weeks | Drug | PCOS patients were treated with metformin orally for 12 weeks, and various indicators related to fertility were observed. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Luteinizing hormone in serum | Changes of luteinizing hormone(mIU/mL) in serum after the intervention. | before and after 2, 12 weeks of intervention |
| 4-Androstenedione in serum | Changes of 4-Androstenedione(pmol/L) in serum after the intervention. | before and after 2, 12 weeks of intervention |
| Measure | Description | Time Frame |
|---|---|---|
| Testosterone in serum | Changes of testosterone(nmol/L) in serum after the intervention. | before and after 2, 12 weeks of intervention |
| Estradiol in serum | Changes of estradiol(pmol/L) in serum after the intervention. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Qiaojie, Professor | Peking University Third Hospital | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Peking University Third Hospital | Beijing | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011085 | Polycystic Ovary Syndrome |
| ID | Term |
|---|---|
| D010048 | Ovarian Cysts |
| D003560 | Cysts |
| D009369 | Neoplasms |
| D010049 | Ovarian Diseases |
| D000291 |
Not provided
Not provided
| ID | Term |
|---|---|
| D008687 | Metformin |
| ID | Term |
|---|---|
| D001645 | Biguanides |
| D006146 | Guanidines |
| D000578 | Amidines |
| D009930 | Organic Chemicals |
Not provided
Not provided
Volunteers with polycystic ovary syndrome without insulin resistance and intervened with metformin for 12 weeks
Not provided
Not provided
Not provided
Not provided
|
| before and after 2, 12 weeks of intervention |
| Prolactin in serum | Changes of prolactin(ng/mL) in serum after the intervention. | before and after 2, 12 weeks of intervention |
| Follicle number | The number of all antral follicles in each ovary will be determined using transvaginal ultrasonography for each participant. | after 12 weeks of intervention |
| Follicle number | The number of all antral follicles in each ovary will be determined using transvaginal ultrasonography for each participant. | before intervention |
| Ovarian volume | The size of each ovary will be determined using transvaginal ultrasonography for each participant in early follicular phase. | after 12 weeks of intervention |
| Ovarian volume | The size of each ovary will be determined using transvaginal ultrasonography for each participant in early follicular phase. | before intervention |
| The alterations of plasma lipid metabolites | Determination the alterations of lipid metabolites before and after metformin intervention by metabolomics. | after 12 weeks of intervention |
| The alterations of plasma lipid metabolites | Determination the alterations of lipid metabolites before and after metformin intervention by metabolomics. | after 2 weeks of intervention |
| The alterations of plasma lipid metabolites | Determination the alterations of lipid metabolites before and after metformin intervention by metabolomics. | before intervention |
| Fasting insulin | Changes in plasma insulin concentration after the intervention. | before and after 2, 12 weeks of intervention |
| Blood sugar level | Changes in plasma glucose concentration after the intervention. | before and after 2, 12 weeks of intervention |
| The alterations of secondary metabolites of gut fungi and bacteria | Determination the alterations of secondary metabolites of gut fungi and bacteria before and after metformin intervention by metabolomics | after 12 weeks of intervention |
| The alterations of secondary metabolites of gut fungi and bacteria | Determination the alterations of secondary metabolites of gut fungi and bacteria before and after metformin intervention by metabolomics | after 2 weeks of intervention |
| The alterations of secondary metabolites of gut fungi and bacteria | Determination the alterations of secondary metabolites of gut fungi and bacteria before and after metformin intervention by metabolomics | before intervention |
| The species and genus abundance changes of fungi and bacteria gut microbiota composition | Determination the species and genus abundance changes of gut microbiota among before and after intervention by ITS genomic | before and after 2, 12 weeks of intervention |
| Follicular stimulating hormone in serum | Changes of follicular stimulating hormone(mIU/mL) in serum after the intervention. | before and after 2, 12 weeks of intervention |
| Adnexal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |
| D006058 | Gonadal Disorders |
| D004700 | Endocrine System Diseases |